Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127413011 | 12741301 | 1 | I | 20110820 | 20160914 | 20160914 | EXP | US-ROCHE-798401 | ROCHE | 0.00 | F | Y | 79.20000 | KG | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127413011 | 12741301 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 1 | 125085 | 1640 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 2 | 125085 | 1580 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 3 | 125085 | 1520 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 4 | 125085 | 1490 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 5 | 125085 | 1470 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (10 MG/KG) CYCLE 6?LAST DOSE PRIOR TO SAE: PAIN IN EXTREMITY (EPISODE 3) | 125085 | 700 | MG | SOLUTION FOR INFUSION | |||||||
| 127413011 | 12741301 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | ON DAYS 1,8, 15, 22 ?LAST DOSE PRIOR TO SAE 22/JUN/2010 | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127413011 | 12741301 | 1 | Endometrial cancer |
| 127413011 | 12741301 | 7 | Endometrial cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127413011 | 12741301 | HO |
| 127413011 | 12741301 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127413011 | 12741301 | Blood bilirubin increased | |
| 127413011 | 12741301 | Pain in extremity | |
| 127413011 | 12741301 | Upper gastrointestinal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127413011 | 12741301 | 6 | 20100615 | 20100622 | 0 | |
| 127413011 | 12741301 | 7 | 20100125 | 20100622 | 0 |